(NewsDirect)
EmyriaLtd (ASX:EMD) MD Michael Winlo tells Proactive the company hasexpanded its proprietary cannabinoid medicine pipeline, with thelaunch of a high potency, highly bioavailable Ultra-Pure CBD dose formcalled EMD-RX9, targeting prescription-based registrations. The launchfollows the company’s recent commercialisation success of itslow-dose CBD capsule, EMD-RX5 with AspenPharmacare (JSE:APN) in Australia.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.